天演藥業 ADAG 深 滬
已收盤 08-01 16:00:00 美东时间
1.92
-0.070
-3.52%
華盛通- 最 高1.99
- 今 開1.99
- 成交量 9972股
- 最 低 1.91
- 昨 收 1.99
- 總市值 9045.04万
- 52周最高 3.5807
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 1.325
- 委 比 75.08%
- 總股本 4710.96万
- 歷史最高 31.83
- 量 比 0.27
- 振 幅 4.02%
- 歷史最低 0.90
- 每 手 1
- 風險率 0.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股最新评级 | 中金公司维持高盛跑赢行业评级，目标价755美元
财联社7月21日讯（编辑 齐灵） 以下为各家券商对美股的最新评级和目标价： 招商证券(香港)维持百度（BIDU.O）买入评级，目标价130.3美元: 招商证券认...
07-21 16:00
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
Adagene announced outcomes from its FDA Type B meeting regarding the clinical development of ADG126, an anti-CTLA-4 SAFEbody, in combination with KEYTRUDA for MSS CRC. The FDA aligned on Phase 2 inclusion/exclusion criteria, endpoints, and design, including sample size and dosing. The Phase 2 trial will randomize patients to 10 mg/kg or 20 mg/kg of ADG126 with pembrolizumab, aiming to identify the optimal dose for Phase 3. The primary endpoint is...
07-15 11:00
Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate
Adagene has partnered with ConjugateBio to provide a proprietary antibody for the development of novel bispecific ADCs. Adagene will receive upfront, milestone, and royalty payments, while retaining non-ADC rights to the antibody. The partnership leverages Adagene’s antibody discovery capabilities and ConjugateBio’s ADC development expertise, targeting solid tumors with innovative therapeutics.
07-08 11:00
25亿美元BD后，MNC追投苏州药企2500万美元
（转自：动脉新医药） 7 月1日，赛诺菲拟向天演药业进行总额最高可达2500万美元的战略投资。此次资金将主要用于推进产品研发，重点支持抗CTLA-4 SAFE...
07-02 18:19
Sanofi Invests Up to $25M in Adagene to Advance Cancer Drug Trials
Adagene Inc. ("Adagene or the Company") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced strategic investment and option exercise by Sanofi (Euronext:
07-01 19:09
Adagene announces up to $25 million strategic investment from Sanofi
- Sanofi invests up to $25 million in Adagene and exercises option on a third SAFEbody program. Proceeds to fund ADG126's clinical development in MSS CRC and combination trials. Adagene retains global rights to ADG126. SAFEbody technology aims to enhance antibody safety and efficacy. Cash runway extended into 2027.
07-01 11:00
Adagene Files For Offering Of Up To $100M American Depositary Shares Representing Ordinary Shares
- SEC Filing
05-31 05:12
Adagene to Present at Jefferies Global Healthcare Conference 2025
Adagene Inc. announced that its Chief Strategy Officer, Mickael Chane-Du, will participate in investor meetings and a fireside chat at the Jefferies Global Healthcare Conference 2025 in New York on June 3-5. The fireside chat will take place on June 5 at 9:20-9:50 AM ET, and a webcast will be available on the company’s investor website for 30 days. Adagene is a clinical-stage biotech company specializing in antibody-based cancer immunotherapies, ...
05-27 11:30
Adagene shares are trading higher after the company revealed updated data from its Phase 1b/2 study of Muzastotug in combination with KEYTRUDA in colorectal cancer at the American Society of Clinical Oncology annual meeting.
Adagene shares are trading higher after the company revealed updated data from ...
05-24 03:54
Adagene Reports Promising ADG126 Study Results at ASCO
Adagene ( ($ADAG) ) has provided an update. Adagene Inc. announced updated data...
05-23 05:26
